secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001178913-26-000300
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio expands OPKO pact to include oral LA-PTH; appoints OPKO exec Rubin to board
--------------------------------------------------------------------------------

- Expanded collaboration covers once-daily oral LA-PTH tablet for hypoparathyroidism; 50/50 cost sharing.
- IND filing for LA-PTH expected late 2026 after positive PK/PD data in December 2025.
- Gerry Ostrov resigned as director effective Feb 1, 2026; Steven Rubin appointed as Class III director.
- Rubin also chairs audit committee and serves on compensation committee; he is EVP at OPKO.
- Oral OXM program progressing; Phase 1 injectable OXM data expected late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/0001178913-26-000300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326000300/zk2634279.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-000300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer